IP6K1 and obesity due to melanocortin 4 receptor deficiency: The pharmacological roles of IP6K1 have undergone extensive exploration in recent years, with emerging evidence suggesting that inhibitors of this kinase and its isoforms hold promise for the treatment of obesity and related metabolic disorders.